Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BugSpeaks is a gut microbiome profiling and analysis platform developed by Leucine Rich Bio, a precision medicine company based in India. The platform utilizes advanced shotgun metagenomic sequencing to analyze the genetic material of the entire microbial community in the human gut, including bacteria, fungi, and viruses. By leveraging proprietary bioinformatics algorithms, BugSpeaks generates a comprehensive Gut Health Score and identifies susceptibility to various chronic diseases. The service provides personalized recommendations for nutrition, prebiotics, and probiotics tailored to an individual's unique microbial signature. It is designed to assist healthcare professionals in managing conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and metabolic disorders. BugSpeaks represents a significant advancement in the application of microbiome science for personalized wellness and clinical decision support in the South Asian market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BugSpeaks.